Skip to content
‹ Back to IndustriesHealthcare

Hearing Aids to Reach Millions With FDA Over-the-Counter Approval

(Bloomberg Law) — Nearly 30 million US adults impacted by hearing loss will now have easier access to hearing aids under a final rule from the FDA allowing them to be purchased over the counter. The action, which finalizes an October 2021 draft rule, would establish a separate medical device category for certain air-conduction hearing…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Hearing Aids to Reach Millions With FDA Over-the-Counter Approval

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

(Bloomberg Law) — Nearly 30 million US adults impacted by hearing loss will now have easier access to hearing aids under a final rule from the FDA allowing them to be purchased over the counter.

The action, which finalizes an October 2021 draft rule, would establish a separate medical device category for certain air-conduction hearing aids used among people 18 years old and older with mild to moderate hearing issues. The new rule stems from President Joe Biden‘s sweeping mandate to crack down on monopolistic practices in agriculture, technology, pharmaceuticals, and other industries. Biden’s order instructed the FDA to take actions within 120 days that would allow hearing aids to be sold over the counter.

“Hearing loss is a critical public health issue that affects the ability of millions of Americans to effectively communicate in their daily social interactions,” FDA Commissioner Robert M. Califf said in a statement. “Establishing this new regulatory category will allow people with perceived mild to moderate hearing loss to have convenient access to a wide array of safe, effective, and affordable purchasing options from their neighborhood store or online.”

The FDA, along with the final rule, issued guidance differentiating between hearing aids and personal sound amplification products, which help people with normal hearing ability amplify sounds in certain environments. Hearing aids are regulated as medical devices by the FDA, unlike sound amplification products, whose manufacturers aren’t subject to product registration requirements.

The 2017 FDA user fee reauthorization included provisions for the FDA to conduct rulemaking to establish an over-the-counter category for hearing aids. The bipartisan legislation also called for the agency to establish safety and effectiveness requirements for products that fall in this category.

Califf said in a call with reporters Tuesday that only about one-fifth of Americans who experience hearing loss seek intervention with the help of hearing aids or other care, due in part to their high costs and the stigma of being perceived as old or disabled. The FDA estimates that the introduction of more over-the-counter hearing aids could lead to roughly $2,800 in savings per pair. Americans currently looking to acquire these products may have to pay up to $5,000 per pair, according to the agency.

In addition to reducing costs for patients, the final rule will “unleash new innovation, which ultimately will mean better quality products and lower prices,” Brian Deese, the White House Director of the National Economic Council, said in Tuesday’s call.

The final rule will take effect in 60 days, and Americans could start seeing over-the-counter hearing aids available at drug and retail stores as soon as mid-October, the FDA said.

Maintaining Safety

The FDA received more than 1,000 comments on the 2021 proposed rule. The Hearing Industries Association told the agency that strict safety and efficacy standards were needed for over-the-counter hearing aids because since 2017, products have entered the market that were “ineffective, of poor quality, and in some cases, dangerous.”

The final rule includes several changes based on the public comments it received, including lowering the maximum sound output of over-the-counter devices to reduce the risk of sound overamplification. It also includes a revised limit to the depth the device can reach in the ear canal, and requires that all hearing aids sold over the counter include a user-adjustable volume control.

The action from FDA is “a significant step forward for the millions of Americans who suffer hearing loss yet are untreated,” HIA President Kate Carr said in a press release. “Hearing loss is unique to each person, and most do not know if their condition is mild, moderate, or greater, caused by another medical issue or something as simple as ear wax.”

“HIA supports the final rule and recommends that the best treatment for hearing loss involves seeing a hearing professional,” Carr added.

The FDA said in its rule that over-the-counter hearing aids will limit cost and medical visit barriers for many, but that it “is not suggesting that licensed persons or their professional services are unimportant or not valuable.”

“We recommend consulting licensed persons in several circumstances, including for the diagnosis of hearing impairment and in the fitting and continued use of OTC hearing aids when consumers choose to seek such services,” the agency said.

Driving Competition

Biden administration officials and policy analysts say the final rule will improve barriers to competition that will benefit both industry and consumers.

Many Americans with mild to moderate hearing impairment have traditionally needed prescriptions from a licensed provider to get a hearing aid, which Deese said Tuesday served as a “barrier to entry” that “kept more companies, or more innovators, from entering the market to compete.”

“That not only limited who could enter the market and get distribution, but the bundling of hearing aids with exams also reduced competition by making it harder for consumers to comparison shop for the best deal,” he added.

Medicare doesn’t cover the costs of hearing aids, or exams for fitting the aids. This has made hearing aids less desirable among many who could benefit from them.

“Hearing aids for the vast majority of Americans are a complete out of pocket expense,” Frank Lin, director of the Johns Hopkins University Cochlear Center for Hearing and Public Health, said in an interview. He added that the FDA in its final rule “struck the right balance” between “fostering safety while ensuring efficacy,” and allowing innovation and competition.

Sens. Elizabeth Warren (D-Mass.) and Chuck Grassley (R-Iowa), who together introduced the Over-the-Counter Hearing Aid Act that Congress passed with user fee reauthorization legislation in 2017, said in a joint statement Tuesday that they’re “thrilled that the FDA has finalized these guidelines.”

“Safe, effective, accessible and affordable hearing aids will now be available over-the-counter for millions of Americans,” they said.

To contact the reporter on this story: Celine Castronuovo at ccastronuovo@bloombergindustry.com

To contact the editors responsible for this story: Cheryl Saenz at csaenz@bloombergindustry.com; Alexis Kramer at akramer@bloomberglaw.com

More stories like this are available on bloomberg.com.

©2022 Bloomberg L.P.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Nearly 500 hospitals track shortage-affected segments via RFID

Nearly 500 hospitals track shortage-affected segments via RFID

According to Bluesight, nearly 500 hospitals track almost 4,000 shortage-affected medication segments in their RFID systems. Checks of cabinets and carousels have been missing that RFID-tracked supply. Gilman argues that bringing RFID data in next to cabinet data gives more complete usage rates and days-on-hand calculations, though the gain could depend on whether systems connect at the transaction level.

  • 01During a shortage, a count that stops at the dispensing cabinet can get both stock on hand and usage rate wrong, which is how hospitals end up placing emergency orders they may not need.
  • 02RFID is no longer limited to kit and tray management: nearly 500 hospitals already track almost 4,000 shortage-affected medication segments in their RFID systems.
  • 03For operators weighing a merged feed, the key question could be whether RFID usage flows into the days-on-hand calculation at the transaction level or sits beside cabinet data as a static count.

Nov 4, 2026

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3 2026, up 36% year over year. Nationally, Rock Health counted $3.7 billion raised by U.S. digital health startups across 114 deals in the quarter. Bigger checks and steady acquisitions mean buyers must assess which vendors are pulling ahead—and which may change owners mid-rollout.

  • 01New York's digital health startups grew Q3 funding 36% year over year, while U.S. digital health startups raised $3.7 billion across 114 deals in Q3, according to Rock Health.
  • 02Average U.S. digital health deal size has climbed from $20.6 million in 2024 to $31.0 million so far in 2026, so more of the money is going into bigger rounds.
  • 03Acquisition is still how most digital health companies exit, with 164 deals through Q3 2026 and no new public listings since August 2025. That makes a vendor's change-of-ownership terms a live contract question for buyers.

Nov 4, 2026

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512